DIRS.INFO The most relevant business & tech news

☆ Why weight-loss drugs like Ozempic are a game-changer for the global economy
▼ + stars: | 2024-03-15 | by ( Phil Rosen | ) www.businessinsider.com time to read: +5 min

Capital Economics said weight-loss drugs could be game-changers for the world economy. Eventually, AI could supercharge the healthcare sector, so weight-loss drugs could be just the beginning. Capital Economics noted that share prices fell in 2023 for many fast-food companies as weight-loss drugs gained popularity, though some of those losses have since been pared. Weight-loss drugs and AIGLP-1 drugs' emergence, meanwhile, has happened alongside the explosion of artificial intelligence technology and hype. If so, the economic gains heralded by weight-loss drugs might be just the beginning."

Persons: —, Goldman Sachs, Eli Lilly Organizations: Service, Capital Economics, Nordisk, Organization, Economic Cooperation, Development Locations: Mexico, America, Denmark, Korea

☆ What weight tells us about our health
▼ + stars: | 2024-01-17 | by ( Dr. Sanjay Gupta | ) edition.cnn.com time to read: +12 min

(CNN) — If you’ve been paying attention to health news recently, you may have noticed a subtle but real shift in the way society discusses body weight. Beyond health care dollarsDespite changing attitudes about larger bodies, excess weight does carry a price. From a health care standpoint, it costs the country a lot of money. According to a study published in the journal The Lancet in 2020, 27% of total health care expenditures in 2016 — about $730.4 billion — could be attributed to “modifiable risk factors” for preventable health conditions like cardiovascular disease. That was eight years ago, when our total health care expenditure was $2.7 trillion, according to the study.

Persons: you’ve, We’re, Dr, Fatima Cody Stanford, “, They’re, Adolphe Quetelet, Ancel Keys, ”, ” Stanford, Morgan, That’s, we’ll, Daniel Lieberman, who’ll, Oprah Organizations: CNN, American Medical Association, Massachusetts General Hospital, Harvard Medical School, National, bloodwork, Harvard Locations: Belgian

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. The U.S. Food and Drug Administration on Wednesday said Eli Lilly (LLY.N) could begin selling its drug tirzepatide for weight loss, making it the second obesity drug in a class known as GLP-1s. Studies of Novo's Wegovy showed that it led to 15% weight loss over 68 weeks, while Lilly's drug, which also targets a second hormone called GIP, demonstrated weight loss of more than 22% over 72 weeks. Drugstore chain Walgreens is seeing "enormous demand" for GLP-1s, said John Driscoll, president, U.S. healthcare at Walgreens Boots Alliance (WBA.O). Much has been made of the impact the new weight loss drugs might have on consumer habits such as snack food purchases, but Driscoll said Walgreens has not seen that yet.

Persons: Victoria Klesty, Eli Lilly, Novo, Novo's Wegovy, Lawrence Tabak, John Driscoll, Tabak, Driscoll, Walgreens, Julie Steenhuuysen, Caroline Stauffer, Deena Beasley, Jamie Freed Organizations: REUTERS, Rights, Reuters, Total Health, U.S . Food, Drug Administration, U.S . National Institutes of Health, Walgreens, Walgreens Boots Alliance, Thomson Locations: Oslo, Norway, August31, Victoria, Chicago, U.S, satiety

☆ Working women spend $15.4 billion more than men in out-of-pocket health costs, study finds
▼ + stars: | 2023-09-26 | by ( Bertha Coombs | ) www.cnbc.com time to read: +1 min

High health care costs are hitting women in the U.S. workforce much harder than men. Working women spend $15.4 billion more in out-of-pocket health expenses annually compared to their male counterparts, according to a new analysis of employer-sponsored health plans from Deloitte Consulting. The study found women spend 18% more than men on co-pays and deductibles, on average. The takeaway being that women get paid less, and that they pay more for health care," said Dr. Kulleni Gebreyes, U.S. chief health equity officer at Deloitte Consulting. Women tend to utilize more medical care than men, in part due to annual gynecological exams and the high costs of breast cancer imaging.

Persons: Kulleni Gebreyes Organizations: Deloitte Consulting, Deloitte Locations: U.S

☆ Billion-dollar physical-therapy startup Sword Health shares the strategies it's using to drive growth ahead of a potential IPO
▼ + stars: | 2023-09-03 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +4 min

Sword Health wants to be profitable before an IPO, and it's aiming to hit that milestone in 2024. Virgilio Bento founded Sword Health in 2015 to give patients around the world access to virtual physical therapy. Bento isn't interested in taking Sword public before the company is profitable, he said, a milestone he expects to reach next year. "And I don't want to be a public company that's not profitable because that puts us in a very tricky situation." Sword Health uses wearables to monitor user movement and provide physical therapy virtually.

Persons: Virgilio Bento, Sword, Bento isn't, Bento, hadn't, he's, hasn't Organizations: Health, Sword Health, Smart

☆ ‘Barbie’ movie’s ending is an important reminder for women’s health
▼ + stars: | 2023-07-26 | by ( Madeline Holcombe | ) edition.cnn.com time to read: +9 min

The final scene in "Barbie" is important for normalizing women's health, CNN Medical Analyst Dr. Leana Wen said. Jaap Buitendijk/Courtesy of Warner Bros. PicturesCNN: Do we give enough attention to women’s reproductive health? Dr. Leana Wen: Reproductive health care is still not regarded as part of total health and well-being. It solidifies the understanding that reproductive health is an integral part of overall health. This is a general preventive health visit in which the health care provider begins to establish a relationship of trust with the patient in a one-on-one, confidential setting.

Persons: “ Barbie, ”, Ruth Handler, Barbie, Leana Wen, Margot Robbie, Jaap Buitendijk, Barbie ”, Wen, normalizes, Pap Organizations: CNN, George Washington University Milken Institute School of Public Health, Warner Bros . Pictures CNN, American College of Obstetricians

☆ Few patients continue weight loss drugs like Wegovy after a year — but health costs soar for all
▼ + stars: | 2023-07-11 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023. And a group of patients in the analysis who didn't take a weight loss drug saw their health-care costs decrease by 4% on average during the same time period. Weight loss drugs are also known as GLP-1 agonists, which mimic a hormone produced in the gut to suppress a person's appetite. Prime Therapeutics' analysis does not indicate why patients stopped taking weight loss drugs. But experts say the medicines may further perpetuate a dangerous diet culture that idealizes weight loss and thinness.

Persons: Joseph Leach, Eli Lilly, Elon Musk Organizations: Novo Nordisk, CNBC, Prime Therapeutics, Food and Drug Administration, Therapeutics, Reuters, Pfizer, National Institutes of Health Locations: Chicago , Illinois, U.S, Danish

☆ Exclusive: Most patients using weight-loss drugs like Wegovy stop within a year, data show
▼ + stars: | 2023-07-11 | by ( Chad Terhune | ) www.reuters.com time to read: +4 min

The annual cost of overall care for patients prior to taking Wegovy or a similar drug was $12,371, on average, according to the analysis. The costs for a similar control group of patients not taking the drugs decreased by 4% over the same period. The analysis by Prime Therapeutics, a pharmacy benefits manager (PBM), reviewed pharmacy and medical claims data for 4,255 people with commercial health plans. For the analysis, Prime Therapeutics excluded patients with type 2 diabetes to focus on obesity treatment. In trials with adults, Novo found that 6.8% of patients taking Wegovy discontinued treatment due to gastrointestinal problems and other adverse events.

Persons: Wegovy, Khrysta Baig, Patrick Gleason, Novo, aren't, Gleason, David Lassen, Lassen, Chad Terhune, Michele Gershberg, Bill Berkrot Organizations: Reuters, Vanderbilt University, Novo Nordisk, Prime Therapeutics, Therapeutics, U.S, Blue, Thomson Locations: Danish

☆ The rise and fall of Birchbox, the once-buzzy startup valued at nearly $500 million that frustrated customers are now saying has 'vanished'
▼ + stars: | 2023-03-11 | by ( Avery Hartmans | ) www.businessinsider.com time to read: +7 min

Birchbox pioneered the monthly beauty subscription box and was once valued at nearly $500 million. The company also raised another round of funding, this time $60 million, which pushed the startup's valuation to $485 million. Meanwhile, Sephora had launched a monthly beauty box of its own. Meanwhile, Birchbox's subscriber count was dropping, and the company raised its monthly subscription price for the first time in its history. Customers are now accusing Birchbox of having 'vanished'Birchbox's monthly box includes sample sizes of high-end beauty products.

Long a source of pride, Canada's publicly funded healthcare system has been strained to the breaking point due to factors including the pandemic and staffing shortages. Here are some of the issues facing Canada's health system:WHAT ARE THE MAIN CHALLENGES? A shortage of healthcare workers fueled in part by burnout and attrition has plagued Canada's hospitals, clinics and primary care resources. Total health spending in Canada was expected to reach C$331 billion in 2022, or C$8,563 per Canadian, according to the Canadian Institute for Health Information. This could include improvements in data collection and the provision of mental health care, among other things.

☆ $5.7 billion Cityblock Health is planning 'aggressive' growth. Its CEO lays out how expanding mental-health services and dealmaking might be in the cards.
▼ + stars: | 2022-11-21 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +5 min

Cityblock Health isn't putting its growth on pause as a recession looms. But Cityblock Health isn't slowing down. The startup's plans for growth include expanding its mental-health and maternal-health services, Ajayi said, adding that the company could also make some acquisitions. Cityblock isn't looking to buy any companies that work with members outside Medicaid and Medicare. While Cityblock can afford to ride out a recession, the startup isn't ignoring the market downturn, Ajayi said.

☆ $5.7 billion Cityblock Health is planning 'aggressive' growth. Its CEO shares how the startup wants to use M&A and more mental-health services to make that happen.
▼ + stars: | 2022-11-21 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +5 min

Cityblock Health isn't putting its growth on pause as a recession looms. But Cityblock Health isn't slowing down. The startup's "aggressive" plans for growth include expanding its mental-health and maternal-health services, Ajayi said, adding that the company could also make some acquisitions. Cityblock isn't looking to buy any companies that work with members outside Medicaid and Medicare. While Cityblock can afford to ride out a recession, the startup isn't ignoring the market downturn, Ajayi said.

Search resuls for: "Total Health"

12 mentions found